Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · October 10, 2022

Treatment With the Antisense Oligonucleotide Tofersen for SOD1 ALS

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
N. Engl. J. Med 2022 Sep 22;387(12)1099-1110, TM Miller, ME Cudkowicz, A Genge, PJ Shaw, G Sobue, RC Bucelli, A Chiò, P Van Damme, AC Ludolph, JD Glass, JA Andrews, S Babu, M Benatar, CJ McDermott, T Cochrane, S Chary, S Chew, H Zhu, F Wu, I Nestorov, D Graham, P Sun, M McNeill, L Fanning, TA Ferguson, S Fradette

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading